CME Group Inc. (CME) Stock Price & How to Invest

CME Group operates the largest futures and options marketplace in the world, spanning six asset classes: interest rates, equity indexes, energy, agricultural commodities, metals and foreign exchange. It earns money mainly from clearing and transaction fees charged on every contract traded and cleared, plus market-data and information-services revenue, and it benefits from owning both the exchange and the clearinghouse that guarantees trades. Volumes rise with hedging demand and market volatility, which is why record average daily volume has been the main engine of recent results.

The investment picture is that of a wide-moat, capital-light franchise with operating margins near 65 to 70 percent and heavy free-cash-flow generation, which funds a regular quarterly dividend plus a variable year-end dividend that together produce a high headline yield. The trade-offs are a full valuation for an exchange, sensitivity to interest-rate activity and volatility cycles, and emerging competitive and regulatory threats (FMX in Treasury futures, perpetual-futures offerings from crypto venues) that could pressure the moat over time.

Revenue is cyclical and tied to trading volumes, so a prolonged low-volatility environment can depress activity and fees. Competition is intensifying: FMX targets U.S. Treasury and SOFR futures with LCH clearing, ICE dominates Brent energy, and Cboe leans on VIX and options flow. A newer threat is regulated perpetual futures from crypto venues such as Coinbase and Kalshi, which the market fears could eventually breach the regulatory moat protecting high-margin retail products like 0DTE options. The stock also trades at a premium exchange multiple, so any volume slowdown or fee compression can weigh on the shares.

15 analysts publish price targets on CME, averaging $283.93 against a $267.79 price as of August 2026, or +6.0%. The published targets run from $230.00 to $330.00, a moderate spread, and the ratings split 9 buy, 4 hold, 3 sell. Over the last six months there have been 4 raises and 6 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CME forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on CME Group Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Record trading volumes. Average daily volume hit a record 36.2 million contracts in Q1 2026, up 22 percent year over year with records across all six asset classes. The most optimistic published target, $330.00, assumes this works close to its best case.

The case against. Revenue is cyclical and tied to trading volumes, so a prolonged low-volatility environment can depress activity and fees. The most pessimistic target, $230.00, is roughly what CME is worth if this bites instead.

Read the full bull and bear case on CME, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see CME Group Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$6.7B
• FY2025 revenue: ~$6.5B
• Net income (TTM): ~$4.2B
• Market cap: ~$87B
• P/E (trailing): ~21x
• Dividend yield: ~4.6% (incl. variable)

CME posted record FY2025 revenue of about $6.5 billion and net income near $4.1 billion, then opened 2026 with record Q1 revenue of roughly $1.88 billion, up 14 percent, and adjusted EPS of $3.36. The shares trade around $240 for a market cap near $87 billion, a trailing P/E of roughly 21, with a high blended dividend yield reflecting the regular-plus-variable payout structure.

If you want CME exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses CME naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to CME: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CME exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (DIVO), which spreads the position across many companies. Or build it into a focused thematic portfolio, so CME sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CME fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

CME is a dominant, high-margin derivatives-exchange franchise whose growth tracks trading volumes and market volatility while facing slow-building competitive threats to its regulatory moat.

Whether CME is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CME a buy or a sell?, and where the stock could go from here in the CME stock forecast.

For income investors, whether CME pays a dividend and how the payout looks is covered in does CME pay a dividend? And to weigh CME against a peer, read the full side-by-side comparisons: CME vs AXP and CME vs BAC.